QQQ
-10.03
371.75
-2.77%
BTC/USD
-2685.65
37995.26
-6.6%
DIA
-4.78
352.11
-1.38%
SPY
-8.46
455.21
-1.89%
TLT
+ 1.69
140.25
+ 1.19%
GLD
-0.62
172.27
-0.36%

Expert Ratings For Pacira BioSciences

November 5, 2021 12:14 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Expert Ratings For Pacira BioSciences

Within the last quarter, Pacira BioSciences (NASDAQ:PCRX) has observed the following analyst ratings:

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 3 2 0 0 0
Last 30D 0 1 0 0 0
1M Ago 3 0 0 0 0
2M Ago 0 1 0 0 0
3M Ago 0 0 0 0 0

According to 5 analyst offering 12-month price targets in the last 3 months, Pacira BioSciences has an average price target of $86.6 with a high of $92.00 and a low of $80.00.

Below is a summary of how these 5 analysts rated Pacira BioSciences over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the move negative analysts are on the stock

price target chart

This average price target has increased by 0.7% over the past month.

How Are Analyst Ratings Determined?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.

Posted-In:

Analyst Ratings

Related Articles

Where Pacira BioSciences Stands With Analysts

Where Pacira BioSciences Stands With Analysts

Pacira BioSciences (NASDAQ:PCRX) has observed the following analyst ratings within the last quarter: read more

Barclays Maintains Overweight on Pacira BioSciences, Raises Price Target to $96

Barclays maintains Pacira BioSciences (NASDAQ:PCRX) with a Overweight and raises the price target from $92 to $96. read more

Barclays Maintains Overweight on Pacira BioSciences, Raises Price Target to $92

Barclays maintains Pacira BioSciences (NASDAQ:PCRX) with a Overweight and raises the price target from $91 to $92. read more

HC Wainwright & Co. Maintains Buy on Pacira BioSciences, Raises Price Target to $86

HC Wainwright & Co. analyst Oren Livnat maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $80 to $86. read more